产品
编 号：F612444
分子式：C24H29NaO5
分子量：420.48
分子式：C24H29NaO5
分子量：420.48
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 496807-11-5
产品详情
生物活性：
Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation. Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
Beraprost sodium (oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.Animal Model:6-8-week-old C57Bl/6J Male Mice
Dosage:0.6?mg/kg
Administration:Oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days
Result:Mitigated the development of renal interstitial fibrosis.
体外研究：
Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation. Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
体内研究：
Beraprost sodium (oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.Animal Model:6-8-week-old C57Bl/6J Male Mice
Dosage:0.6?mg/kg
Administration:Oral adminstration; 0.6?mg/kg; once daily; 3 or 7 days
Result:Mitigated the development of renal interstitial fibrosis.
体外研究：
Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0?μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备